What Opsumit (MACITENTAN) Treats: Main Uses and Benefits

Opsumit (macitentan) is commonly used for the management of Pulmonary Arterial Hypertension (PAH), a chronic condition where high blood pressure in the arteries of the lungs creates noticeable physiological strain. The medication is generally used to provide therapeutic support across multiple symptom-focused domains.

The medication is considered relevant to assist in managing the potential for disease progression and PAH-related hospitalization. This therapeutic focus may assist in managing the risks associated with the condition's trajectory. Macitentan is typically applied in clinical settings for the management of the most common PAH symptoms, including shortness of breath and fatigue.

The use of Opsumit is relevant across domains where additional symptomatic support is needed, and it may assist with easing the overall symptom load. This approach may contribute to improved day-to-day comfort during symptomatic periods and may support general well-being. It is considered relevant in contexts where maintaining a sense of stability is important when symptoms are more noticeable.

This treatment is used to support ongoing management across conditions characterized by periods of heightened symptoms against a progressive vascular disorder. It may provide support during difficult episodes by assisting with easing distress and may contribute to a more manageable experience of routine activities.

Quick Fact: Supportive Management for Symptom Clusters

Who Can and Cannot Use Opsumit (Macitentan)

Opsumit is approved for use in adults with Pulmonary Arterial Hypertension (PAH). Regulatory agencies strictly define the populations for whom the medicine is contraindicated or requires restricted use.

Absolute Contraindications

The medicine is strictly contraindicated for several groups based on official labeling:

• Pregnant females due to confirmed embryo-fetal toxicity risk.
• Individuals with known hypersensitivity to macitentan or any component of the product.
• Patients with severe hepatic impairment (Child-Pugh Class C) or elevated baseline liver aminotransferases (AST/ALT greater than 3 times the Upper Limit of Normal).

Population Restrictions and Conditional Use

Population Group	Regulatory Status
Females of Reproductive Potential	Use is restricted and requires participation in a mandatory risk management program (e.g., REMS) involving contraception and monthly pregnancy testing.
Pediatric Patients (Under 18)	Use is not recommended by the FDA as safety and efficacy have not been established. (Use is permitted for children 2 years and older in some regions).
Severe Renal Impairment	Caution is advised; use is not recommended for patients undergoing dialysis.
Moderate Hepatic Impairment	Not recommended (Child-Pugh Class B).
Lactating Women	Not recommended; women should not breastfeed during treatment.

Interaction Map: Official Regulatory Information for Opsumit (MACITENTAN)

Macitentan's interaction profile is strongly influenced by the Cytochrome P450 (CYP) enzyme system, which metabolizes the drug. Interactions may significantly alter the concentration of macitentan in the blood.

Category	Regulatory Requirement / Statement
Exposure-Increasing Interactions	Co-administration with strong CYP3A4 inhibitors (e.g., Ketoconazole, Ritonavir) should be avoided as they can approximately double macitentan exposure. Dual inhibitors of CYP3A4 and CYP2C9 (e.g., Fluconazole) are predicted to increase exposure four-fold, and concomitant use must also be avoided.
Exposure-Reducing Interactions	Co-administration with strong CYP3A4 inducers (e.g., Rifampin) should be avoided as they significantly reduce macitentan plasma levels. The herbal product St. John's Wort is also listed as an inducer that must be avoided.
Documented Non-Interactions	Official studies indicate no clinically relevant interaction with Warfarin (no change in INR) or Sildenafil. The drug can be administered irrespective of food intake.
Transporter Mechanisms	Macitentan is documented as not being a substrate or inhibitor of the key efflux transporter P-glycoprotein (P-gp).

Interaction-Context Constraints: For patients who require strong CYP3A4 inhibitors as part of treatments like HIV therapy, regulatory documents advise considering other Pulmonary Arterial Hypertension (PAH) treatment options. The restrictions against strong CYP modulators are the highest level of constraint applied to co-administration in the macitentan label.

Macitentan functions as a dual Endothelin Receptor Antagonist (ERA), targeting the ET-1 signaling cascade. The drug achieves its effect by blocking the two primary receptors, Endothelin Receptor Type A ( ET A) and Type B ( ET B), with high affinity and sustained receptor occupancy due to slow dissociation kinetics.

Blocking the Molecular Triggers of Vasoconstriction

Macitentan interrupts the ET-1 signal that binds to the ET A receptor on pulmonary arterial smooth muscle cells. By physically blocking this receptor, the drug prevents the resulting surge of intracellular calcium that forces the muscle cells to contract. This mechanistic domain immediately reduces the pathological vascular tone, initiating the physiological consequence of pulmonary vasodilation and lowering resistance to blood flow.

Inhibiting Structural Vascular Remodeling

Antagonism of both ET A and ET B receptors attenuates the signaling cascades that promote the proliferation and growth of the vessel wall cells. This action limits the progressive thickening of the arteries, thereby contributing to the vessel diameter remaining open, which results in a sustained decrease in Pulmonary Vascular Resistance (PVR).

Systemic Hemodynamic Consequence

The combined effect of immediate vasodilation and the inhibition of cellular proliferation leads to the key systemic consequence: a decrease in the pressure load exerted on the right ventricle of the heart. The reduced resistance in the pulmonary circulation results in a modulation of the system’s pressure profile.

How to Use Opsumit (MACITENTAN)

Opsumit is administered as an oral film-coated tablet for the long-term management of pulmonary arterial hypertension. Treatment is intended to be chronic and must be initiated and monitored by a healthcare professional experienced in treating the condition.

---

Standard Administration Principles

The standard regimen for Opsumit is a single 10 mg tablet taken once daily. This 10 mg is the maximum recommended dose. To maintain consistent systemic exposure, the medication should be taken at approximately the same time each day. It can be taken either with or without food.

Administration Rule	Procedural Detail
Tablet Integrity	The film-coated tablet must be swallowed whole with water. It is explicitly instructed not to crush, split, or chew the tablet.
Missed Dose	If a once-daily dose is missed, it should be taken as soon as the lapse is remembered on the same day. Patients must not take two doses at the same time to compensate for a missed dose.

---

Use in Specific Populations

Dosing rules are standardized for several specific populations, defining the consistent application of the 10 mg dose. Older adults (aged 65 years and over) do not require a dose adjustment. Similarly, no adjustment is specified for patients with mild or moderate hepatic impairment or for those with renal impairment not requiring dialysis. Use is generally not recommended for patients undergoing dialysis. For pediatric patients starting at 2 years of age, a weight-based regimen using a dispersible tablet formulation is used, with the 10 mg dose applicable to those weighing 40 kg or more.

Research evidence / Overview of studies for Opsumit (MACITENTAN)

---

Evidence for use in Pulmonary Arterial Hypertension (PAH)

The research base for macitentan in PAH includes a single, large-scale, long-term, event-driven Randomized Controlled Trial (RCT). This study type is used to assess clinical outcomes over time. This pivotal study was observed in adult patients with symptomatic PAH (WHO Functional Class II–IV), including those new to treatment and those receiving background PAH therapy. The research examined a comprehensive, composite endpoint that monitored the time to the first occurrence of several defined clinical outcomes (including clinical worsening, hospitalization, or death).

The study populations were monitored for outcomes capturing phases of heightened symptom activity, such as PAH-related hospitalization. Research also examined patient outcomes related to functional capacity, such as the distance patients could walk in six minutes, and how their overall health status was monitored (WHO Functional Class).

---

Research on Other Forms of Pulmonary Hypertension

Macitentan was studied for use in a specific group of adults with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) whose condition was associated with functional limitations or persisted after surgery. Research was conducted primarily through a smaller Phase 2 RCT and its open-label extension.

The main outcomes examined in these studies included hemodynamic markers, such as measurements of pulmonary vascular resistance. Research also examined patient outcomes related to exercise capacity and overall functional classification in the observed populations. These findings were based on modest sample sizes and the controlled study period follow-up durations were limited.

---

Long-Term Evidence and Extended Follow-up

Long-term follow-up was monitored through uncontrolled open-label extension studies after the original pivotal RCT was conducted over approximately two years. These studies describe group patterns for survival and event-free status over periods of up to five years or more. While these long-term studies provide valuable context, the fact that they were uncontrolled means the level of certainty regarding the long-term effects remains low compared to the initial RCT.

---

Research in Specific Patient Groups

The primary RCT was evaluated in a broad population that included patients with PAH secondary to connective tissue disease and those with idiopathic (unknown cause) PAH. Research was studied for use in adolescents (ge 12 years of age) who were observed in the overall population of the main trial. However, the data for certain patient groups, such as very older adults or those with specific severe comorbidities, remain insufficient in the published reports.

---

What Research Gaps Remain Uncharted

Several research limitations are still emerging. The pivotal RCT was studied for a composite morbidity/mortality endpoint, meaning the study was not powered to determine the effect on all-cause death alone. Therefore, the certainty regarding this specific, single outcome remains low. Additionally, data for certain groups remain insufficient, including evidence for the long-term use in the pediatric population. The research provides context but not individual predictions.

Key Studies & References

1. Macitentan for inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from a multicentre, double-blind, randomised, placebo-controlled right heart catheterisation substudy

Common questions about Opsumit (MACITENTAN) (FAQ)

---

Q: How is Opsumit different from other medicines used for PAH?

Opsumit (macitentan) is classified as a dual Endothelin Receptor Antagonist (ERA), meaning it works by blocking two types of receptors, ET A and ET B, in the blood vessels. Official documents describe this action as a high-affinity, sustained receptor occupancy. This pharmacological profile is a key feature that distinguishes it within the class of medicines used for Pulmonary Arterial Hypertension (PAH).

Q: Is Opsumit the same kind of drug as Tracleer (bosentan)?

Opsumit and Tracleer belong to the same pharmacological class, Endothelin Receptor Antagonists (ERAs). However, the official descriptions detail macitentan’s distinct chemical structure and its optimized profile regarding how it binds to the receptors in the pulmonary arteries. While they share a drug class, they are not the same medicine.

Q: What is the difference between macitentan and ambrisentan?

Macitentan is described in regulatory documents as blocking both the ET A and ET B receptors to manage PAH. In contrast, ambrisentan is described as an ERA that is selective for only the ET A receptor. These differences relate to their specific actions on the cell signaling pathway.

Q: What is the main reason a doctor would prescribe Opsumit?

Opsumit is indicated for the treatment of Pulmonary Arterial Hypertension (PAH) to reduce the risks associated with the disease. Official information states its use is intended to slow down the progression of PAH and reduce the likelihood of PAH-related hospitalization.

Q: Does Opsumit actually cure the condition it treats?

Opsumit is not described in official documents as a cure for Pulmonary Arterial Hypertension (PAH). It is indicated for the long-term management and treatment of the condition to help mitigate risks associated with disease progression.

Q: How long does it usually take to see any effect from Opsumit?

The main clinical study used to establish effectiveness was a long-term trial that observed patients for an average of two years. A significant improvement in the ability to exercise was observed in the study population as early as Month 6. Conversely, the most common side effect, anemia (low red blood cell count), typically develops within the first weeks of starting treatment.

Q: Is Opsumit a type of chemotherapy or cancer drug?

Opsumit is pharmacologically classified as a dual Endothelin Receptor Antagonist (ERA). Its function is to block the effects of endothelin, a natural substance, in order to help relax blood vessels in the lungs. It is not approved or indicated for the treatment of cancer.

Q: Do I need to take Opsumit for the rest of my life?

Treatment with Opsumit is intended for the chronic management of Pulmonary Arterial Hypertension (PAH). The official information indicates that the need for long-term therapy is determined by a healthcare professional based on the individual's condition.

Q: Does the time of day I take Opsumit matter?

The official prescribing information states that the medicine should be taken at approximately the same time each day. This principle helps maintain a consistent level of the drug in the body over time, supporting the chronic management of the condition.

Q: What happens if I forget to take Opsumit one day?

If a once-daily dose is missed, regulatory information advises that it should be taken as soon as the lapse is remembered on the same day. Patients are specifically instructed not to double the dose by taking two tablets at the same time to compensate for the missed dose.

Q: Is it common to feel tired when first starting Opsumit?

Anemia (low red blood cell count), which can cause unusual tiredness or weakness, is a Very Common side effect of Opsumit, meaning it occurs in more than 1 in 10 patients. Regulatory documents note that the decrease in hemoglobin typically occurs early in the course of treatment, leading to frequent reporting of fatigue.

Q: Does Opsumit cause hair loss?

Hair loss (alopecia) is not listed in the official table of common, uncommon, or rare adverse reactions documented in the clinical studies for Opsumit.

Q: Can Opsumit affect the results of other lab tests?

The official safety profile requires routine laboratory monitoring, specifically of hemoglobin levels (due to the risk of anemia) and hepatic transaminases (liver enzymes). These values are monitored because they can be affected by the treatment.

Q: Can men use Opsumit?

Opsumit is approved for use in adults, and men are included in the patient population. Official labeling includes information specifically for Males of Reproductive Potential regarding the potential for decreased sperm counts observed in animal studies.

Q: Is Opsumit safe to take with birth control pills?

Regulatory studies have shown no clinically relevant effect on the drug levels of the active components (norethisterone and ethinyl estradiol) found in some oral contraceptives. However, females of reproductive potential are strictly mandated to use effective contraception throughout treatment.

Q: Are there specific foods or drinks I should avoid while on Opsumit?

Opsumit can be taken with or without food. However, regulatory documents state that strong CYP3A4 inducers, such as the herbal product St. John's Wort, must be avoided because they can significantly reduce the level of Opsumit in the bloodstream.

Q: What does the FDA say about Opsumit's effectiveness?

The FDA determined Opsumit’s effectiveness based on a large, long-term study. This study showed that Opsumit reduced the risks of disease progression and hospitalization for Pulmonary Arterial Hypertension (PAH) in the observed patient population.

Q: Is it okay to drink alcohol in moderation while taking Opsumit?

Official documents do not specifically mention an interaction between Opsumit and alcohol. However, Opsumit carries a documented risk of liver injury (hepatotoxicity). Due to this risk, patients are advised to report symptoms suggesting hepatic injury to their healthcare provider.

Q: Does Opsumit cause weight gain or weight loss?

Weight changes are not specifically listed as side effects. However, fluid retention, which can cause swelling and weight gain, is a Common side effect observed in clinical studies and is a known effect of this class of drugs.

Q: Is Opsumit a steroid?

The active ingredient, macitentan, is a synthetic, non-steroidal compound. It is pharmacologically classified as a dual Endothelin Receptor Antagonist (ERA), designed to block receptors in the blood vessels.

Q: What should I do if a side effect seems to get worse after a few weeks?

Official guidelines emphasize the need for regular monitoring and advise patients to report symptoms suggesting serious adverse effects, such as signs of liver injury (like nausea, fatigue, or jaundice), to their healthcare provider. Routine laboratory tests are performed specifically to monitor these key risks.

Q: What happens if I suddenly stop taking Opsumit?

Opsumit is a long-term treatment indicated to reduce the risks of PAH disease progression. Discontinuing the medicine is expected to reintroduce those risks. Any decision to stop or interrupt treatment is made only under the guidance of a healthcare professional.

Q: Can Opsumit cause anxiety or mood changes?

Anxiety is not listed in the official table of common adverse reactions. However, insomnia (difficulty sleeping) and depression were reported as common psychiatric adverse reactions in clinical studies.

Q: Does Opsumit make you more sensitive to the sun?

Increased sensitivity to the sun (photosensitivity) is not listed in the official tables detailing the common, uncommon, or rare adverse reactions associated with Opsumit.

Q: What if I travel to a different time zone—should I adjust my Opsumit dose time?

The medicine should be taken at approximately the same time each day to maintain consistent blood levels. Patients are typically advised to discuss medication schedule adjustments for travel or time zone changes with their prescribing doctor.

Q: Is it normal to have some swelling in the legs while taking Opsumit?

Swelling in the legs, known as peripheral edema or fluid retention, is a Common side effect that was observed in clinical studies. Fluid retention is a documented and known effect of this class of drugs.

Q: Why is Opsumit sometimes taken with other PAH medications?

Opsumit’s effectiveness was established in a pivotal study that included patients taking the medicine alone or in combination with other Pulmonary Arterial Hypertension (PAH) medicines. This combination approach is often used to target different disease mechanisms simultaneously, a strategy supported by the research evidence.

Q: Can I use Opsumit if I have low blood pressure?

Opsumit works by helping to lower pressure in the pulmonary arteries, and hypotension (low blood pressure) was observed as an adverse reaction in clinical studies. Patients with underlying conditions are cautioned, and the decision to use the drug in these cases is made by a healthcare professional.

Q: What are the long-term effects of taking Opsumit?

Long-term follow-up data, with median patient exposure of about two years, supports the reduction of risks of disease progression. The long-term safety profile emphasizes the need for routine monitoring of the liver and blood (for anemia), as well as the risk of decreased sperm counts in males.

Q: Does Opsumit cause problems with sleep?

Insomnia (difficulty sleeping) was reported as a common adverse reaction in the clinical studies for Opsumit.

Q: Who manufactures Opsumit?

According to official product information, Opsumit is manufactured by Actelion Pharmaceuticals US, Inc., which is part of Janssen Pharmaceuticals, Inc.

How to Store and Dispose of Opsumit (Macitentan)

Opsumit tablets must be stored at controlled room temperature, specifically between 68°F and 77°F (20°C and 25°C). The medicine must be kept in its original package and a closed container, and should be protected from heat, moisture, and direct light.

It is an official requirement that Opsumit must not be frozen. As a mandatory safety constraint, the medicine must be stored out of the reach and sight of children.

For disposal, unused or expired Opsumit should be discarded in accordance with local requirements. Users are instructed to consult a healthcare professional, such as a pharmacist or doctor, for guidance on the proper disposal of any medicine that is no longer needed.